Effectiveness and safety of bedaquiline, pretomanid, linezolid and moxifloxacin in drug-resistant tuberculosis patients in selected public hospitals in Ethiopia: a multicenter retrospective cohort study
A multicenter retrospective cohort study assesses BPaLM treatment outcomes in drug-resistant tuberculosis, indicating high effectiveness and manageable safety.
Key Points
This study aims to evaluate the effectiveness and safety of the BPaLM regimen in treating drug-resistant tuberculosis in Ethiopia.
Retrospective cohort design using patient records from selected public hospitals
Included 104 patients treated with the BPaLM regimen
Data on demographics and clinical characteristics were extracted and analyzed
Descriptive statistics and Kaplan-Meier curves were used for analysis
94% of patients had good treatment outcomes
Culture conversion rates were 48% at 30 days, 78% at 60 days, and 93% at 90 days
Adverse events were reported in 15% of patients, with 4.8% experiencing serious adverse events leading to hospitalization